Bavarian Nordic stock jumps after U.S. orders 2.5 million more monkeypox vaccine doses


The U.S.-listed shares of Bavarian Nordic A/S BVNRY, +3.40% BAVA, +0.56% jumped 2.0% in afternoon trading Friday, after the Denmark-based drug maker said the U.S. government has ordered 2.5 million additional doses of liquid-frozen JYNNEOS, the only monkeypox vaccine approved by the U.S. Food and Drug Administration. The new order comes a day after the FDA completed an inspection of the plant where the two-dose vaccine is manufactured. Bavarian Nordic said the additional orders follows two previous orders from the U.S. Biomedical Advanced Research and Development Authority (BARDA) in in June for 500,000 doses and in July for 2.5 million doses, which including an order in 2020 for 1.4 million doses, brings total deliveries to 6.9 million doses in 2022 and 2023. Bavarian Nordic’s stock has shot up 43.4% over the past three months, while the iShares MSCI Denmark Capped ETF EDEN, +1.55% has lost 13.1% and the S&P 500 SPX, +1.67% has shed 12.3%.

This article was originally published by Read the original article here.

Previous article: AMC may have been a meme-stock darling, but weakness in some key areas has the company on shaky ground
Next articleCoronavirus Update: Unicef, WHO sound alarm on childhood-vaccination backslide


Please enter your comment!
Please enter your name here